Across TCGA pan-cancer cohorts, FTLP17 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of FTLP17’s most consistent transcriptional readouts.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where FTLP17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FTLP17 is over-expressed in tumor, although a few such as LUSC and LUAD show the opposite, repressed pattern.
LIHC, HNSC, and COAD are the cancer types where FTLP17 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FTLP17 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.